Trending Now - Eli Lilly and Insilico Medicine Forge $2.75B AI Drug Partnership

WHO:

CNBC - Rachel You, CFO of Innovent Biologics, stated that China's obesity drug market has massive potential.

CNBC - Alex Zhavoronkov, founder and CEO of Insilico Medicine, stated that Eli Lilly has "one person" who has brought biology, chemistry, and automation under one roof.

CNBC - Eli Lilly, a U.S. pharmaceutical giant, and Insilico Medicine, a Hong Kong-listed AI drug discovery company.

CNBC - Alex Zhavoronkov, founder and CEO of Insilico Medicine.

CNBC - Andrew Adams, group vice president of Molecule Discovery at Eli Lilly.

CNBC - David A. Ricks, CEO of Eli Lilly.

WHAT:

CNBC - Eli Lilly plans to invest $3 billion in China over the next decade.

CNBC - Eli Lilly reported that slightly less than 3% of its revenue came from China in 2025.

CNBC - The remainder of the $2.75 billion deal is subject to regulatory and commercial milestones, along with royalties on future sales.

CNBC - Insilico Medicine went public in Hong Kong in December 2025.

CNBC - Eli Lilly and Insilico Medicine signed a drug co-development deal worth up to $2.75 billion.

CNBC - The deal includes $115 million in upfront payments to Insilico Medicine.

CNBC - Insilico Medicine has developed at least 28 drugs using generative AI tools, with nearly half at a clinical stage.

CNBC - Insilico's shares are up more than 50% year-to-date.

WHERE:

CNBC - The agreement was announced in Beijing, China.

CNBC - Insilico Medicine is based in Hong Kong.

WHEN:

CNBC - Eli Lilly CEO David A. Ricks attended a high-level forum in Beijing on March 6th, 2026.

CNBC - The AI-based software licensing agreement between Eli Lilly and Insilico Medicine was signed in 2023.

CNBC - Eli Lilly CEO David A. Ricks attended a high-level forum in Beijing earlier in March 2026.

WHY:

CNBC - Rachel You expressed optimism about the potential of the obesity drug market in China, suggesting it could mirror current penetration rates in the U.S.

CNBC - Andrew Adams, group vice president of Molecule Discovery at Lilly, stated that the collaboration allows for the exploration of novel mechanisms and acceleration of the identification of promising therapeutic candidates across multiple disease areas.

CNBC - The collaboration aims to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas.

CNBC - Insilico's AI-enabled discovery is considered a powerful complement to Lilly's clinical development.

HOW:

CNBC - Eli Lilly's collaboration with Insilico Medicine aims to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas.

CNBC - As part of the deal, Insilico will join Lilly's Gateway Labs community for biotech development.

CNBC - Insilico Medicine will join Lilly's Gateway Labs community for biotech development as part of the deal.

(UPDATED March 30, 2026 17:18 UTC)

Eli Lilly plans to invest $3 billion in China over the next decade, as the company aims to tap into the growing obesity drug market, which Innovent Biologics CFO Rachel You believes has massive potential. During a high-level forum in Beijing March 6th, Eli Lilly CEO David A. Ricks highlighted that less than 3% of the company's revenue came from China in 2025, indicating room for growth. The collaboration with Insilico Medicine will focus on exploring novel mechanisms and speeding up the identification of promising therapeutic candidates across various disease areas.

(UPDATED March 30, 2026 05:40 UTC)

Insilico Medicine's CEO, Alex Zhavoronkov, highlighted that Eli Lilly has a key individual who integrates biology, chemistry, and automation in their operations. The $2.75 billion deal between the two companies includes regulatory and commercial milestones, as well as royalties on future sales, and Insilico went public in Hong Kong in December 20th25. This collaboration, which will see Insilico join Lilly's Gateway Labs community for biotech development, aims to explore new mechanisms and speed up the identification of promising therapeutic candidates across various disease areas.

(UPDATED March 29, 2026 21:04 UTC)

Eli Lilly and Insilico Medicine have signed a significant drug co-development deal worth up to $2.75 billion, which includes $115 million in upfront payments to Insilico. The agreement, announced in Beijing, aims to leverage Insilico's AI-enabled discovery capabilities to accelerate the identification of promising therapeutic candidates across various disease areas. As part of the collaboration, Insilico will join Lilly's Gateway Labs community for biotech development, enhancing their partnership in drug discovery.